---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012413"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-08-21T23:59:59+00:00"
generated_at: "2026-05-31T08:12:07.233346+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path reports solid tumor patient response to BP1001-A; AML patients show extended remission

## Summary
- First patient at 90 mg/m2 dose of BP1001-A had 15% tumor reduction and stable disease after 6 cycles.
- Patient is elderly female with gynecologic cancer, heavily pretreated with chemotherapy and surgeries.
- Two elderly AML patients in Phase 2 triple combo (prexigebersen/decitabine/venetoclax) remain in complete remission: one at 16 cycles/21 months, another at 12 cycles/14 months.
- Phase 1b of BP1001-A expected to begin after three monotherapy dose cohorts; will test combo with paclitaxel and gemcitabine.
- Management highlights platform potential for targeted protein inhibition with favorable safety profile.

## SEC filing metadata
- accession: 0001558370-24-012413
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-08-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024012413/0001558370-24-012413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024012413/bpth-20240821x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012413
- JSON: https://secwatch.observer/filing/0001558370-24-012413.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.